CD30/CD30 ligand and CD40/CD40 ligand in malignant lymphoid disorders

International Journal of Biological Markers

Volumn 14, Issue 3, 1999, Pages 135-143

  Younes, A ^a   Carbone, A ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

EBV; Hodgkin's disease; LMP; Lymphoma; Reed Sternberg cells; TNF

Indexed keywords

CD30 ANTIGEN; CD30 LIGAND; CD40 ANTIGEN; GLYCOPROTEIN GP 39; LIGAND; MEMBRANE PROTEIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

HODGKIN DISEASE; HUMAN; LYMPHOMA; REED STERNBERG CELL; REVIEW;

PHRAGMITES;

EID: 0032751560     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460089901400303     Document Type: Review

References (115)

1. Stein H, Gerdes J, Schwab U, et al. Evidence for the detection of the normal counterpart of Hodgkin and Sternberg-Reed cells. Hematol Oncol a 1983; 1: 21-9.
2. Durkop H, Latza U, Hummel M, Eitelbach F, Seed B, Stein H. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 1992; 68: 421-7.
3. Smith CA, Gruss HJ, Davis T, et al. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 1993; 73: 1349-60.
4. Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985; 66: 848-58.
5. Clark EA, Ledbetter JA. Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50. Proc Natl Acad Sci USA 1986; 83: 4494-8.
6. Paulie S, Ehlin-Henriksson B, Mellstedt H, Koho H, BenAissa H, Perlmann P. A p50 surface antigen restricted to human urinary bladder carcinomas. Cancer Immunol Immunother 1985; 20: 23-8.
7. Stamenkovic I, Clark EA, Seed B. A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas. Embo J 1989; 8: 1403-10.
8. Armitage RJ, Fanslow WC, Strockbine L, et al. Molecular and biological characterization of a murine ligand for CD40. Nature 1992; 357: 80-2.
9. Armitage RJ, Sato TA, Macduff BM, et al. Identification of a source of biologically active CD40 ligand. Eur J Immunol 1992; 22: 2071-6.
10. Gruss HJ, Dower SK. Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. Blood 1995; 85: 3378-404.
11. Chiarle R, Podda A, Prolla G, Gong J, Thorbecke GJ, Inghirami G. CD30 in normal and neoplastic cells. Clin Immunol 1999; 90: 157-64.
12. de Bruin PC, Gruss HJ, van der Valk P, Willemze R, Meijer CJ. CD30 expression in normal and neoplastic lymphoid tissue: biological aspects and clinical implications. Leukemia 1995; 9: 1620-7.
13. D'Elios MM, Romagnani P, Scaletti C, et al. In vivo CD30 expression in human diseases with predominant activation of Th2-like T cells. J Leukoc Biol 1997; 61: 539-44.
14. Del Prete G, Maggi E, Pizzolo G, Romagnani S. CD30, Th2 cytokines and HIV infection: a complex and fascinating link. Immunol Today 1995; 16: 76-80.
15. Del Prete G, De Carli M, Almerigogna F, et al. Prefer-ential expression of CD30 by human CD4+ T cells producing Th2- type cytokines. Faseb J 1995; 9: 81-6.
16. Romagnani P, Annunziato F, Manetti R, et al. High CD30 ligand expression by epithelial cells and Hassal's corpuscles in the medulla of human thymus. Blood 1998; 91: 3323-32.
17. Falini B, Pileri S, Pizzolo G, et al. CD30 (Ki-1) mole-cule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 1995; 85: 1-14.
18. Chan JK, Ng CS, Hui PK, et al. Anaplastic large cell Ki-1 lymphoma. Delineation of two morphological types. Histopathology 1989; 15: 11-34.
19. Delsol G, Al Saati T, Gatter KC, et al. Coexpression of epithelial membrane antigen (EMA), Ki-1, and interleukin-2 receptor by anaplastic large cell lymphomas. Diagnostic value in so-called malignant histiocytosis. Am J Pathol 1988; 130: 59-70.
20. Greer JP, Kinney MC, Collins RD, et al. Clinical features of 31 patients with Ki-1 anaplastic large-cell lymphoma. J Clin Oncol 1991; 9: 539-47.
21. Inghirami G, Macri L, Cesarman E, Chadburn A, Zhong J, Knowles DM. Molecular characterization of CD30+ anaplastic large-cell lymphoma: high frequency of c-myc proto-oncogene activation. Blood 1994; 83: 3581-90.
22. Kadin ME. Primary Ki-1-positive anaplastic large-cell lymphoma: a distinct clinicopathologic entity. Ann Oncol 1994; 5: S25-30.
23. Kaudewitz P, Stein H, Dallenbach F, et al. Primary and secondary cutaneous Ki-1+ (CD30+) anaplastic large cell lymphomas. Morphologic, immunohistologic, and clinical characteristics. Am J Pathol 1989; 135: 359-67.
24. Pileri SA, Piccaluga A, Poggi S, et al. Anaplastic large cell lymphoma: update of findings. Leuk Lymphoma 1995; 18: 17-25.
25. Carbone A, Gloghini A, Gaidano G, Dalla-Pavera R, Falini B. BCL-6 protein expression in human peripheral T-cell neoplasms is restricted to CD30+ anaplastic large-cell lymphomas. Blood 1997; 90: 2445-50.
26. Cabanillas F, Armitage J, Pugh WC, Weisenburger D, Duvic M. Lymphomatoid papulosis: a T-cell dyscrasia with a propensity to transform into malignant lymphoma. Ann Int Med 1995; 122: 210-7.
27. Oudejans JJ, Dukers DF, Jiwa NM, et al. Expression of Epstein-Barr virus encoded nuclear antigen 1 in benign and malignant tissues harbouring EBV. J Clin Pathology 1996; 49: 897-902.
28. Reynolds DJ, Banks PM, Gulley ML. New characterization of infectious mononucleosis and a phenotypic comparison with Hodgkin's disease. Am J Pathol 1995; 146: 379-88.
29. Horie R, Watanabe T. CD30: expression and function in health and disease. Semin Immunol 1998; 10: 457-70.
30. Pizzolo G, Romagnani S. CD30 molecule (Ki-1 Ag): more than just a marker of CD30+ lymphoma. Haematologica 1995; 80: 357-66.
31. Latza U, Foss HD, Durkop H, et al. CD30 antigen in embryonal carcinoma and embryogenesis and release of the soluble molecule. Am J Pathol 1995; 146: 463-71.
32. Horn-Lohrens O, Tiemann M, Lange H, et al. Shedding of the soluble form of CD30 from the Hodgkin-analogous cell line L540 is strongly inhibited by a new CD30-specific antibody (Ki-4). Int J Cancer 1995; 60: 539-44.
33. Pizzolo G, Vinante F, Chilosi M, et al. Serum levels of soluble CD30 molecule (Ki-1 antigen) in Hodgkin's disease: relationship with disease activity and clinical stage. Br J Haematol 1990; 75: 282-4.
34. Nadali G, Tavecchia L, Zanolin E, et al. Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome. Blood 1998; 91: 3011-6.
35. Pizzolo G, Vinante F, Nadali G, et al. High serum level of soluble CD30 in acute primary HIV-1 infection. Clin Exp Immunol 1997; 108: 251-3.
36. Okumura M, Hidaka Y, Kuroda S, Takeoka K, Tada H, Amino N. Increased serum concentration of soluble CD30 in patients with Graves' disease and Hashimoto's thyroiditis. J Clin Endocrinol Metab 1997; 82: 1757-60.
37. Giacomelli R, Cipriani P, Lattanzio R, et al. Circulating levels of soluble CD30 are increased in patients with systemic sclerosis (SSc) and correlate with serological and clinical features of the disease. Clin Exp Immunol 1997; 108: 42-6.
38. Gerli R, Muscat C, Bistoni O, et al. High levels of the soluble form of CD30 molecule in rheumatoid arthritis (RA) are expression of CD30+ T cell involvement in the inflamed joints. Clin Exp Immunol 1995; 102: 547-50.
39. Fattovich G, Vinante F, Giustina G, et al. Serum levels of soluble CD30 in chronic hepatitis B virus infection. Clin Exp Immunol 1996; 103: 105-10.
40. Nadali G, Vinante F, Ambrosetti A, et al. Serum levels of soluble CD30 are elevated in the majority of untreat-ed patients with Hodgkin's disease and correlate with clinical features and prognosis. J Clin Oncol 1994; 12: 793-7.
41. Zinzani PL, Pileri S, Bendandi M, et al. Clinical implications of serum levels of soluble CD30 in 70 adult anaplastic large-cell lymphoma patients. J Clin Oncol 1998; 16: 1532-7.
42. Younes A, Consoli U, Snell V, et al. CD30 ligand in lymphoma patients with CD30+ tumors. J Clin Oncol 1997; 15: 3355-62.
43. Gruss HJ. Molecular, structural, and biological characteristics of the tumor necrosis factor ligand superfamily. Int J Clin Lab Res 1996; 26: 143-59.
44. Clodi K, Younes A. Reed-Sternberg cells and the TNF family of receptors/ligands. Leuk Lymphoma 1997; 27: 195-205.
45. Gruss HJ, Herrmann F. CD30 ligand, a member of the TNF ligand superfamily, with growth and activation control CD30+ lymphoid and lymphoma cells. Leuk Lymphoma 1996; 20: 397-409.
46. Younes A, Consoli U, Zhao S, et al. CD30 ligand is expressed on resting normal and malignant human B lymphocytes. Br J Haematol 1996; 93: 569-71.
47. Pinto A, Aldinucci D, Gloghini A, et al. Human eosinophils express functional CD30 ligand and stimulate proliferation of a Hodgkin's disease cell line. Blood 1996; 88: 3299-305.
48. Gruss HJ, Pinto A, Gloghini A, et al. CD30 ligand expression in nonmalignant and Hodgkin's disease-ined lymphoid tissues. Am J Pathol 1996; 149: 469-81.
49. Gruss HJ, DaSilva N, Hu ZB, Uphoff CC, Goodwin RG, Drexler HG. Expression and regulation of CD30 ligand and CD30 in human leukemia-lymphoma cell lines. Leukemia 1994; 8: 2083-94.
50. Amakawa R, Hakem A, Kundig TM, et al. Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice. Cell 1996; 84: 551-62.
51. Chiarle R, Podda A, Prolla G, Podack ER, Thorbecke GJ, Inghirami G. CD30 overexpression enhances nega-tive selection in the thymus and mediates programmed cell death via a Bcl-2-sensitive pathway. J Immunol 1999; 163: 194-205.
52. Heath WR, Kurts C, Caminschi I, Carbone FR, Miller JF. CD30 prevents T-cell responses to non-lymphoid tissues [In Process Citation]. Immunol Rev 1999; 169: 23-9.
53. Kurts C, Carbone FR, Krummel MF, Koch KM, Miller JF, Heath WR. Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells. Nature 1999; 398: 341-4.
54. Gruss HJ, Ulrich D, Braddy S, Armitage RJ, Dower SK. Recombinant CD30 ligand and CD40 ligand share common biological activities on Hodgkin and Reed-Sternberg cells. Eur J Immunol 1995; 25: 2083-9.
55. Gruss HJ, Hirschstein D, Wright B, et al. Expression and function of CD40 on Hodgkin and Reed-Sternberg cells and the possible relevance for Hodgkin's disease. Blood 1994; 84: 2305-14.
56. Jung W, Krueger S, Renner C, et al. Opposite effects of the CD30 ligand are not due to CD30 mutations: results from cDNA cloning and sequence comparison of the CD30 antigen from different sources. Mol Immunol 1994; 31: 1329-34.
57. Grell M, Zimmermann G, Gottfried E, et al. Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF. Embo J 1999; 18: 3034-43.
58. Gattei V, Degan M, Gloghini A, et al. CD30 ligand is frequently expressed in human hematopoietic malignancies of myeloid and lymphoid origin. Blood 1997; 89: 2048-59.
59. Pera MF, Bennett W, Cerretti DP. Expression of CD30 and CD30 ligand in cultured cell lines from human germ-cell tumors. Lab Invest 1997; 76: 497-504.
60. Gruss HJ, Herrmann F, Gattei V, Gloghini A, Pinto A, Carbone A. CD40/CD40 ligand interactions in normal, reactive and malignant lympho-hematopoietic tissues. Leuk Lymphoma 1997; 24: 393-422.
61. van Kooten C, Banchereau J. Functional role of CD40 and its ligand. Int Arch Allergy Immunol 1997; 113: 393-9.
62. Banchereau J, Bazan F, Blanchard D, et al. The CD40 antigen and its ligand. Annu Rev Immunol 1994; 12: 881-922.
63. Gruss HJ, Herrmann F, Gattei V, Gloghini A, Pinto A, Carbone A. CD40/CD40 ligand interactions in normal, reactive and malignant lympho-hematopoietic tissues. Leuk Lymphoma 1997; 24: 393-422.
64. Young LS, Eliopoulos AG, Gallagher NJ, Dawson CW. CD40 and epithelial cells: across the great divide. Immunol Today 1998; 19: 502-6.
65. Wingett DG, Vestal RE, Forcier K, Hadjokas N, Nielson CP. CD40 is functionally expressed on human breast carcinomas: variable inducibility by cytokines and enhancement of Fas-mediated apoptosis. Breast Cancer Res Treat 1998; 50: 27-36.
66. Gormand F, Briere F, Peyrol S, et al. CD40 expression by human bronchial epithelial cells. Scand J Immunol 1999; 49: 355-61.
67. Banchereau J, Dubois B, Fayette J, et al. Functional CD40 antigen on B cells, dendritic cells and fibroblasts. Adv Exp Med Biol 1995; 378: 79-83.
68. Armitage RJ, Maliszewski CR, Alderson MR, Grabstein KH, Spriggs MK, Fanslow WC. CD40L: a multi-functional ligand. Semin Immunol 1993; 5: 401-12.
69. Callard RE, Armitage RJ, Fanslow WC, Spriggs MK. CD40 ligand and its role in X-linked hyper-IgM syn-drome. Immunol Today 1993; 14: 559-64.
70. Grewal IS, Flavell RA. The role of CD40 ligand in costimulation and T-cell activation. Immunol Rev 1996; 153: 85-106.
71. Rathmell JC, Townsend SE, Xu JC, Flavell RA, Goodnow CC. Expansion or elimination of B cells in vivo: dual roles for CD40- and Fas (CD95)-ligands modulated by the B cell antigen receptor. Cell 1996; 87: 319-29.
72. Spriggs MK, Fanslow WC, Armitage RJ, Belmont J. The biology of the human ligand for CD40. J Clin Immunol 1993; 13: 373-80.
73. De Paoli P, Cozzi M, Tedeschi R, et al. High CD40 membrane expression in AIDS-related lymphoma B cell lines is associated with the CD45RA+, CD45RO+, CD95+ phenotype and high levels of its soluble form in culture supernatants. Cytometry 1997; 30: 33-8.
74. Carbone A, Gloghini A. Diagnostic significance of CD40, CD40L, and CD26 expression in Hodgkin's disease and other lymphomas [letter]. Am J Clin Pathol 1996; 105: 522-3.
75. Clodi K, Snell V, Zhao S, Cabanillas F, Andreeff M, Younes A. Unbalanced expression of Fas and CD40 in mantle cell lymphoma. Br J Haematol 1998; 103: 217-9.
76. Clodi K, Asgary Z, Zhao S, et al. Coexpression of CD40 and CD40 ligand in B-cell lymphoma cells. Br J Haematol 1998; 103: 270-5.
77. Carbone A, Gloghini A, Pinto A. CD40: a sensitive marker of Reed-Sternberg cells [letter]. Blood 1996; 87: 4918-9.
78. O'Grady JT, Stewart S, Lowrey J, Howie SE, Krajewski AS. CD40 expression in Hodgkin's disease [see comments]. Am J Pathol 1994; 144: 21-6.
79. Jakobson E, Jonsson G, Bjorck P, Paulie S. Stimulation of CD40 in human bladder carcinoma cells inhibits anti-Fas/APO-1 (CD95)-induced apoptosis. Int J Cancer 1998; 77: 849-53.
80. Carbone A, Gloghini A, Gruss HJ, Pinto A. CD40 antigen expression on Reed-Sternberg cells. A reliable diag-nostic tool for Hodgkin's disease [letter; comment]. Am J Pathol 1995; 146: 780-1.
81. Carbone A, Weiss LM, Gloghini A, Ferlito A. Hodgkin's disease: old and recent clinical concepts. Ann Otol Rhinol Laryngol 1996; 105: 751-8.
82. Carbone A, Gloghini A. The role of current and new discriminating markers in the immunodiagnosis of Hodgkin's disease and other phenotypically related lymphomas. Pathologica 1996; 88: 169-74.
83. Eliopoulos AG, Dawson CW, Mosialos G, et al. CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr virus-encoded LMP1: involvement of TRAF3 as a common mediator. Oncogene 1996; 13: 2243-54.
84. Hostager BS, Bishop GA. Cutting edge: contrasting roles of TNF receptor-associated factor 2 (TRAF2) and TRAF3 in CD40-activated B lymphocyte differentiation. J Immunol 1999; 162: 6307-11.
85. Pullen SS, Dang TT, Crute JJ, Kehry MR. CD40 signal-ing through tumor necrosis factor receptor-associated factors (TRAFs). Binding site specificity and activation of downstream pathways by distinct TRAFs. J Biol Chem 1999; 274: 14246-54.
86. Devergne O, McFarland EC, Mosialos G, Izumi KM, Ware CF, Kieff E. Role of the TRAF binding site and NF-kappaB activation in Epstein-Barr virus latent membrane protein 1-induced cell gene expression. J Virol 1998; 72: 7900-8.
87. Kehry MR. CD40-mediated signaling in B cells. Balancing cell survival, growth, and death. J Immunol 1996; 156: 2345-8.
88. Izumi KM, McFarland EC, Ting AT, Riley EA, Seed B, Kieff ED. The Epstein-Barr virus oncoprotein latent membrane protein 1 engages the tumor necrosis factor receptor-associated proteins TRADD and receptor-inter-acting protein (RIP) but does not induce apoptosis or require RIP for NF-kappaB activation. Mol Cell Biol 1999; 19: 5759-67.
89. Ardila-Osorio H, Clausse B, Mishal Z, Wiels J, Tursz T, Busson P. Evidence of LMP1-TRAF3 interactions in glycosphingolipid-rich complexes of lymphoblastoid and nasopharyngeal carcinoma cells. Int J Cancer 1999; 81: 645-9.
90. Eliopoulos AG, Blake SM, Floettmann JE, Rowe M, Young LS. Epstein-Barr virus-encoded latent membrane protein 1 activates the JNK pathway through its extreme C terminus via a mechanism involving TRADD and TRAF2. J Virol 1999; 73: 1023-35.
91. Rathmell JC, Goodnow CC. The in vivo balance between B cell clonal expansion and elimination is regulated by CD95 both on B cells and in their micro-environment. Immunol Cell Biol 1998; 76: 387-94.
92. Choi YS. Differentiation and apoptosis of human germinal center B-lymphocytes. Immunol Res 1997; 16: 161-74.
93. Younes A, Snell V, Consoli U, et al. Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukaemia. Br J Haematol 1998; 100: 135-41.
94. Wang D, Freeman GJ, Levine H, Ritz J, Robertson MJ. Role of the CD40 and CD95 (APO-1/Fas) antigens in the apoptosis of human B-cell malignancies. Br J Haematol 1997; 97: 409-17.
95. Planken EV, Willemze R, Kluin-Nelemans JC. The role of the CD40 antigen on malignant B cells. Leuk Lymphoma 1996; 22: 229-35.
96. Grewal IS, Flavell RA. The CD40 ligand. At the center of the immune universe? Immunol Res 1997; 16: 59-70.
97. Toes REM, Schoenberger SP, van der Voort EIH, Offringa R, Melief CJM. CD40-CD40Ligand interactions and their role in cytotoxic T lymphocyte priming and anti-tumor immunity. Semin Immunol 1998; 10: 443-8.
98. Hess S, Engelmann H. A novel function of CD40: induction of cell death in transformed cells. J Exp Med 1996; 183: 159-67.
99. Carbone A, Gloghini A, Gruss HJ, Pinto A. CD40 ligand is constitutively expressed in a subset of T cell lymphomas and on the microenvironmental reactive T cells of follicular lymphomas and Hodgkin's disease. Am J Pathol 1995; 147: 912-22.
100. Carbone A, Gloghini A, Zagonel V, et al. The expression of CD26 and CD40 ligand is mutually exclusive in human T- cell non-Hodgkin's lymphomas/leukemias. Blood 1995; 86: 4617-26.
101. Inghirami G, Lederman S, Yellin MJ, Chadburn A, Chess L, Knowles DM. Phenotypic and functional char-acterization of T-BAM (CD40 ligand)+ T-cell non-Hodgkin's lymphoma. Blood 1994; 84: 866-72.
102. Schattner EJ, Mascarenhas J, Reyfman I, et al. Chronic lymphocytic leukemia B cells can express CD40 ligand and demonstrate T-cell type costimulatory capacity. Blood 1998; 91: 2689-2697.
103. Brown MP, Topham DJ, Sangster MY, et al. Thymic lymphoproliferative disease after successful correction of CD40 ligand deficiency by gene transfer in mice. Nat Med 1998; 4: 1253-60.
104. Carayanniotis G, Masters SR, Noelle RJ. Suppression of murine thyroiditis via blockade of the CD40-CD40L interaction. Immunology 1997; 90: 421-6.
105. Saito K, Sakurai J, Ohata J, et al. Involvement of CD40 ligand-CD40 and CTLA4-B7 pathways in murine acute graft-versus-host disease induced by allogeneic T cells lacking CD28. J Immunol 1998; 160: 4225-31.
106. Koshy M, Berger D, Crow MK. Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest 1996; 98: 826-37.
107. Early GS, Zhao W, Burns CM. Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response. J Immunol 1996; 157: 3159-64.
108. Holder MJ, Wang H, Milner AE, et al. Suppression of apoptosis in normal and neoplastic human B lympho-cytes by CD40 ligand is independent of Bc1-2 induction. Eur J Immunol 1993; 23: 2368-71.
109. Ghia P, Boussiotis VA, Schultze JL, et al. Unbalanced expression of bcl-2 family proteins in follicular lymphoma: contribution of CD40 signaling in promoting survival. Blood 1998; 91: 244-51.
110. Voorzanger-Rousselot N, Favrot M, Blay JY. Resistance to cytotoxic chemotherapy induced by CD40 ligand in lymphoma cells. Blood 1998; 92: 3381-7.
111. Romano MF, Lamberti A, Tassone P, et al. Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells. Blood 1998; 92: 990-5.
112. Graf D, Muller S, Korthauer U, van Kooten C, Weise C, Kroczek RA. A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation. Eur J Immunol 1995; 25: 1749-54.
113. Mazzei GJ, Edgerton MD, Losberger C, et al. Recombinant soluble trimeric CD40 ligand is biologically active. J Biol Chem 1995; 270: 7025-8.
114. Pietravalle F, Lecoanet-Henchoz S, Blasey H, et al. Human native soluble CD40L is a biologically active trimer, processed inside microsomes. J Biol Chem 1996; 271: 5965-7.
115. Vakkalanka RK, Woo C, Kirou KA, Koshy M, Berger D, Crow MK. Elevated levels and functional capacity of soluble CD40 ligand in systemic lupus erythematosus sera. Arthritis Rheum 1999; 42: 871-81.